HCA Healthcare UK named ‘International Cancer Centre of the Year 2016’
HCA Healthcare UK, were the only UK based company to win an award, given by the International Medical Tourism Journal. An international panel of experts judged HCA according to patient satisfaction and the quality and range of services offered including; screening, diagnostics, genetic testing, surgery, chemotherapy, radiotherapy, and palliative care.
HCA UK’s network of hospitals and facilities in London and Manchester offer cancer patients cutting-edge innovative treatment and consistency of care. HCA UK also provides a Living Well programme through Leaders in Oncology Care, supporting patients above, beyond and after their treatment.
HCA UK has invested in making sure the latest technologies are available to patients, this includes investing in a NanoKnife, a pioneering treatment for inoperable pancreatic cancer.
HCA UK is also at the forefront of clinical research through the Sarah Cannon Research Institute, a unique standalone trial facility working closely with clinical investigators to develop new and innovative cancer therapies for patients.
CEO of HCA Healthcare UK, Mike Neeb said;
“From research to cutting edge treatment right though to aftercare, HCA Healthcare UK is proud of the care we give to our patients across our network of hospitals and facilities.
“This award recognises our high level of care and expertise in cancer treatment and demonstrates why so many people from the UK and around the world choose HCA.”
This is not the first success for HCA UK’s cancer care. HCA’s techniques to personalise cancer care and help improve quality of life for patients were recognised in a double win at the LaingBuisson awards in November 2015. The Christie Clinic, collaboration between HCA and The Christie NHS Foundation Trust in Manchester, was recognised for work it has done to personalise cancer care and redesign the patient pathway to better support patients receiving radiotherapy.
The Harley Street Clinic was also awarded for the development of a study to spare hair follicles of patients undergoing radiotherapy to the brain to reduce hair loss and improve speed of regrowth following treatment.